Image Courtesy : colossalbiosciences.com
Colossal Biosciences, the Dallas-based biotechnology company best known for its ambitious de‑extinction efforts, is pursuing a dramatic increase in valuation as it enters new funding discussions. The company is reportedly seeking a valuation between $20 billion and $30 billion, a significant jump from its last known valuation of $10.2 billion. This move reflects Colossal’s transition from a research-focused startup to a diversified deep‑tech enterprise with multiple revenue-generating initiatives.
Over the past year, Colossal has expanded its commercial footprint by offering conservation and genetic technologies to government partners. Both the United States and the United Arab Emirates have begun working with the company, with the UAE investing $60 million to support Colossal’s conservation and biotechnology programs. These partnerships mark a shift toward practical applications of the company’s scientific work, strengthening investor confidence in its long-term business model.
Colossal’s growing valuation is also supported by a network of spinout companies that leverage its core technologies. Breaking focuses on biologically driven plastic degradation, Form Bio provides computational biology tools and recently secured $30 million in funding, and Astromech develops AI-powered predictive modeling and carries a valuation of $2 billion. These ventures broaden Colossal’s reach beyond de‑extinction, creating a multi‑layered ecosystem that appeals to investors seeking exposure to frontier science.
Meanwhile, Colossal continues to advance its core mission of reviving extinct species. The company recently added the bluebuck antelope to its list of de‑extinction targets, joining the woolly mammoth, dodo, Tasmanian tiger, and others. Its nonprofit arm has also partnered with the University of Tasmania to support efforts to protect Tasmanian devils from a contagious facial cancer threatening the species. CEO Ben Lamm has suggested that Colossal’s artificial animal womb technology—originally developed for de‑extinction—may be ready for broader applications next year, including potential use in human fertility research.
As global interest in longevity science, alternative energy, and deep‑tech innovation continues to rise, Colossal Biosciences is positioning itself at the intersection of genetics, AI, and conservation. If successful, its work could eventually contribute to emerging markets such as biodiversity credits, offering new financial incentives for ecological restoration. The company’s pursuit of a $20B–$30B valuation underscores both the scale of its ambitions and the growing investor appetite for transformative scientific ventures.